These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32668011)

  • 41. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998.
    Snell NJ; Ganderton D
    Respir Med; 1999 Feb; 93(2):123-33. PubMed ID: 10464864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinergic influence on the sensitivity of cough reflex in awake guinea-pigs.
    Jia YX; Sekizawa K; Sasaki H
    J Auton Pharmacol; 1998 Oct; 18(5):257-61. PubMed ID: 9831225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulmonary reflexes after human heart-lung transplantation.
    Hathaway T; Higenbottam T; Lowry R; Wallwork J
    Respir Med; 1991 Jan; 85 Suppl A():17-21. PubMed ID: 2034830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
    Walenga RL; Longest PW
    J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary and Regional Deposition of Nebulized and Dry Powder Aerosols in Ferrets.
    Kuehl PJ; Chand R; McDonald JD; Hava DL; DeHaan WH
    AAPS PharmSciTech; 2019 Jul; 20(6):242. PubMed ID: 31264190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What is the role of particle morphology in pharmaceutical powder aerosols?
    Chan HK
    Expert Opin Drug Deliv; 2008 Aug; 5(8):909-14. PubMed ID: 18712999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TRPV1 as a cough sensor and its temperature-sensitive properties.
    Lee LY; Ni D; Hayes D; Lin RL
    Pulm Pharmacol Ther; 2011 Jun; 24(3):280-5. PubMed ID: 21215321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Passive smoke effects on cough and airways in young guinea pigs: role of brainstem substance P.
    Joad JP; Munch PA; Bric JM; Evans SJ; Pinkerton KE; Chen CY; Bonham AC
    Am J Respir Crit Care Med; 2004 Feb; 169(4):499-504. PubMed ID: 14644932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting delivery of aerosols to different lung regions.
    Bennett WD; Brown JS; Zeman KL; Hu SC; Scheuch G; Sommerer K
    J Aerosol Med; 2002; 15(2):179-88. PubMed ID: 12184868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of the tracheobronchial clearance in patients with chronic bronchial infections by an integrated system using radioactive aerosol inhalation scintigraphy].
    Matsui Y; Amitani R; Itoh H; Kuze F
    Bull Chest Dis Res Inst Kyoto Univ; 1991 Mar; 24(1-2):12-33. PubMed ID: 1823860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of clonidine on induced cough and bronchoconstriction in guinea pigs and healthy humans.
    O'Connell F; Thomas VE; Fuller RW; Pride NB; Karlsson JA
    J Appl Physiol (1985); 1994 Mar; 76(3):1082-7. PubMed ID: 8005849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models.
    Acosta MF; Muralidharan P; Meenach SA; Hayes D; M-Black S; Mansour HM
    Curr Pharm Des; 2016; 22(17):2522-31. PubMed ID: 26831643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanotechnology and pharmaceutical inhalation aerosols.
    Patel AR; Vavia PR
    Indian J Exp Biol; 2007 Feb; 45(2):166-74. PubMed ID: 17375556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dry powder inhaler aerosol deposition in a model of tracheobronchial airways: Validating CFD predictions with in vitro data.
    Ahookhosh K; Saidi M; Aminfar H; Mohammadpourfard M; Hamishehkar H; Yaqoubi S
    Int J Pharm; 2020 Sep; 587():119599. PubMed ID: 32663586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aerosol deposition considerations in inhalation therapy.
    Newman SP
    Chest; 1985 Aug; 88(2 Suppl):152S-160S. PubMed ID: 3893925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges.
    Ruge CA; Kirch J; Lehr CM
    Lancet Respir Med; 2013 Jul; 1(5):402-13. PubMed ID: 24429205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A critical analysis of the CFD-DEM simulation of pharmaceutical aerosols deposition in extra-thoracic airways.
    Spasov GH; Rossi R; Vanossi A; Cottini C; Benassi A
    Int J Pharm; 2022 Dec; 629():122331. PubMed ID: 36283644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in pulmonary drug delivery using large, porous inhaled particles.
    Edwards DA; Ben-Jebria A; Langer R
    J Appl Physiol (1985); 1998 Aug; 85(2):379-85. PubMed ID: 9688708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.